Lenvatinib/Pembrolizumab Shows Positive Trends vs Global SOC in Frontline RCC Meta-Analysis
January 27th 2024First-line lenvatinib and pembrolizumab showed similar overall survival rates and improved progression-free survival and response rates vs global standard-of-care immunotherapies among patients with advanced renal cell carcinoma.
Capivasertib Shows Superior PROs Vs Placebo in HR+, HER2- Breast Cancer
December 6th 2023Patient-reported outcomes of the CAPItello-291 study of capivasertib plus fulvestrant showed a positive benefit-risk profile for the combination in patients with HR-positive, HER2-negative advanced breast cancer.
Continued Benefit Shown With Pembrolizumab, Lenvatinib in Endometrial Cancer
October 23rd 2023An exploratory analysis of Study 309/KEYNOTE-775 showed further benefit for patients and consistent safety in patients who received pembrolizumab plus lenvatinib for advanced endometrial cancer who continued lenvatinib treatment.
Multidisciplinary Practice Management Is “Critical” in Lung Cancer
June 16th 2023In an interview with Targeted Oncology, Joshua K. Sabari, MD, discussed practice management strategies as a thoracic medical oncologist, including multidisciplinary care, communication between inpatient and outpatient oncology services, and advice on end-of-life care.
Cytopenias Did Not Affect Ruxolitinib Efficacy in REACH2 Post Hoc Analysis
February 17th 2023Ruxolitinib elicited higher responses at day 28 compared with best available therapy in most cytopenia-based subgroups and had durable responses at day 56, according to a post hoc analysis of the REACH2 trial.
Primary End Point of Improved DFS Not Met With Adjuvant Canakinumab in NSCLC
September 12th 2022Adjuvant treatment with canakinumab did not meet the disease-free survival primary end point in patients with completely resected non–small cell lung cancer versus placebo, nor did subgroup analyses show statistically significant differences in DFS, according to results from the phase 3 CANOPY-A trial presented at ESMO Congress 2022.
Neoadjuvant Nivolumab/Ipilimumab Shows Unprecedented Pathologic Responses in dMMR Colon Cancer
September 11th 2022At the 2022 ESMO Congress, results from the NICHE-2 trial showed neoadjuvant immunotherapy in patients with mismatch repair deficient colon cancer had notable responses to the therapy well above neoadjuvant chemotherapy.
Interim Data Targeting CD117 Show Promising MRD Results and Safety in MDS/AML
April 27th 2022JSP191 combined with fludarabine, and low-dose total body radiation demonstrated facilitation of full donor myeloid chimerism, clearing of minimal residual disease, and a well-tolerated safety profile in older patients with myelodysplastic syndrome/acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.